Lilly slams Times over trials data charge

Lilly took a sharp tone in responding to a New York Times article that the company said “likely created a strong false impression with readers that Lilly suppresses data.”

The Times article, following on a New England Journal of Medicine piece, claimed that Lilly suppressed Prozac clinical trials data.

“Not only was the Times' story inaccurate when it comes to Prozac—the NEJM article didn't identify a single Prozac study as unpublished—but it also likely created a strong false impression with readers that Lilly suppresses data,” the company said in a news release, concluding: “We clearly have been transparent. The data is publicly available online; we've presented it to healthcare professionals at major medical meetings; and we published it—more than once—in peer-reviewed medical journals. And we remain committed to transparency. All of which we would have told The New York Times…if only they had called and asked.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.